#8: Genzyme Corp.
Headcount 10,100
Year Established 1981
Pharma Revenues $3,417 1%
Total Revenues $4,085 3%
Net Income $32 -93%
R&D Budget $847 2%
Top-Selling Drugs in 2010
Drug |
Indication |
$ |
(+/- %) |
Cerezyme |
Gaucher disease |
$720 |
-9% |
Renagel |
hemodialysis |
$698 |
-1% |
Fabrazyme |
Fabry disease |
$188 |
-56% |
Myozyme |
Pompe disease |
$412 |
27% |
Thymoglobulin/Lymphoglobulin |
transplantation | $230 | 6% |
Aldurazyme |
mucopolysaccharidosis |
$167 |
8% |
Thyrogen |
thyroid cancer |
$182 |
7% |
Hectorol |
renal disease |
$190 |
46% |
Account for 82% of total biopharma sales, down from 86% in 2009.
Previous Profile: CSL // Next Profile: Allergan